
PlexPCR[®] VHS

Varicella, Herpes & Syphilis

Confident lesion testing to suit any population



Syphilis rates are on the rise¹⁻³

- Symptomatic/visual lesion diagnostics can have low accuracy (33-80%),⁴⁻⁶ molecular testing is recommended.⁷⁻¹²
- Syphilis lesions can present atypically, be painful, and appear indistinguishable from herpes.^{8,13,14}
- Atypical zoster (VZV) may account for 1-3%¹⁵⁻¹⁷ of genital lesions, misdiagnosis can affect patient psychological wellbeing.





One kit. Two tests.

Individual software modules provide two tests for one validation/verification. The automated analysis is included with the *PlexPCR*[®] VHS lesion diagnostics solution.

SpeeDx Software Module	Targets
SpeeDx Analysis <i>PlexPCR</i> ® HV	HSV-1 HSV-2 VZV
SpeeDx Analysis <i>PlexPCR</i> ® VHS	HSV-1 HSV-2 VZV T. pallidum

- Suitable for high or low risk population testing
- Multiple analysis module options for flexible target analysis
- Choose all four targets or herpes and varicella only
- Modules analysed simulatenously to streamline workflow and data analysis

Fast and reproducible data analysis.


Streamline your workflow and minimise time spent with subjective amplification curves with SpeeDx Analysis software.

The complete **Plex**PCR[®] VHS solution includes:

- Automated result calling
- Simple sample processing
- Validated, high security, GDPR compliance
- Multiple analysis modules with or without syphilis

EALA BRIVES	HINCH INPO	419 HEORD						Results evenius Resolution Details		The Contract of the Second Second Second Second
O Select dualitie A large assignment 8 Construction 1 2 2 <th></th> <th colspan="3">*: N _ kopyet </th> <th></th> <th></th> <th></th> <th>Table filters et Results</th> <th>Assay Cq values Cq</th> <th>Amplification curves</th>		*: N _ kopyet						Table filters et Results	Assay Cq values Cq	Amplification curves
00000000	8	- 000	2442.24	Assay	_	Result	Cq values	Overall results	1	FAM M IOE Town Red TAMRA M CyS
	0	E ResistancePlus M	403	 PlexPCR VHS (7500 PlexPCR VHS 	• •	Positive	JOE 19:30 TAMRA: 26:35	4031 HGN-1 detected		Baseline-corrected ampl (F) (A (
Select all Dealect all Clear whiched Defiet assays		Mi 🔕 🔕 🌘	356	PeoPCR VHS (7500 PeoPCR VHS	• 0	Positive	FAM: 13.80 TAMRA: 26.05 Cy5: 36.35	356 7. palidum, HSV-2 detected		1932/98.66
MEMOLIS STIR			419	 PerPCR VHS (7500) PerPCR VHS 	• 0	Negative	TAMRA: 25:25	413 Negative IC valid.		411398.66
			1047	PerPCR VHS (7500) PerPCR VHS	. 0	Positive	Texas Red: 15.00 TAMRA: 26.65	1047 VZV detected		Cycle NAM 100 100 reass Red 1 SAMRA 10 Cycl
			1048	 PerPCR VHS (7500 PerPCR VHS 	• 0	Negative	TAMRA: 27.45	1048 Negative IC valid.		
			2083.	 PeoPCR VHS (2500) PeoPCR VHS 	- 0	Invalid	TAMRA: 29.70	1051 IC smalld Re-estigat and re-best sample.		

"We strongly believe in having a T. pallidum PCR as part of the routine test for any genito-anal ulcer. Several patients have been found to have syphilis where this was not originally suspected, and blood tests would never have been taken." Dr. Andrew Winter, Consultant in Sexual Health and HIV Medicine, NHS Greater Glasgow and Clyde, UK.







Molecular testing from a syphilis lesion is a direct detection method— simplifying diagnosis and enabling timely partner notification and contact tracing.²¹

> Surveillance or sentinal lesion screening can assist with early

detection.22,23





Atypical lesion presentation can complicate diagnosis.^{8,13-17}



Syphilis at highest rates in decades, including rise in congenital syphilis cases.^{1-4,11}

Increased number of reported syphilis epidemics and outbreaks.²⁴⁻²⁶



PlexPCR[®] VHS is a single-well, mulitplex qPCR test detecting common causes of genital and oral lesions. Detect Herpes simplex virus type-1 & -2 (HSV-1 & HSV-2), and Varicella zoster virus (VZV), with software analysis options to include *Treponema pallidum* (syphilis) detection. *PlexPCR*[®] VHS is powered by *PlexPCR*[®] proprietary technologies for improved multiplex performance compared with other probe-based methods.²⁶

Single-well	Plex PCR [®]	Test
-------------	------------------------------	------

Channel	Target
1	HSV-1
2	HSV-2
3	VZV
4	T. pallidum (optional analysis)
5	Internal Control

Demonstrated clinical performance²⁸

	HSV-1	HSV-2	VZV	TP
Sensitivity	97.7%	100%	100%	100%
Specificity	99.7%	99.7%	99.7%	100%

Validated with non-genital and genital swabs.²⁸

PlexPCR[®] VHS Flexible lesion diagnostics

Product	Compatible	Size	Cat #
	ABI 7500/7500 Fast/Dx	100 reactions	1123001
PlexPCR [®] VHS [*]	LC 480 II	100 reactions	1121001
	CFX IVD, CFX Touch	100 reactions	1125001

References: 1. Australian Institute of Health and Welfare 2018. Australia's health 2018. Australia's health series no. 16. **2**. ECDC surveillance atlas of infectious diseases, syphilis 2015 **3**. CDC Sexually Transmitted Disease Surveillance 2017 **4**. Dangor Y et al. Sex Transm Dis 1990; 17:184–189. **5**. O'Farrell N et al. Genitourin Med 1994; 70: 7–11 **6**. Ndinya-Achola JO et al. Int J STD & AIDS 1996; 7: 201–205 **7**. Workowski KA et al MMWR Recomm Rep 2015;64 (RR03); 25:48 **8**. Janier M et al. 2014 European guideline on the management of syphilis 2015 **13**. Towns JM sex Transm Infect. 2016 genital herpes **11**. Abara WE et al. PLOS ONE Published online 22 July 2016 **12**. Kingston M et al. UK national guidelines on the management of syphilis 2015 **13**. Towns JM Sex Transm Infect. 2016 Mar;92(2):110-5 **14**. Hope-Rapp E et al. J Sex Transm Dis. 2010;37:153-8 **15**. Rübben A et al. Br J Dermatol. 1997;137(2):259–61 **16**. Granato PA et al. J Clin Virol. 2016 Nov:84:87-89 **17**. Birch C et al. Sex Transm Infect. 2003; 79:298-300 **18**. Cunningham S et al. Sex Transm Infect. 2006;82:444-445 **19**. Doherty IA et al. Sex Transm Dis. 2011 May; 38(5): 378–384 **20**. Slutsker JS et al. MMWR Morb Mortal Wkly Rep 2018;67:1088–1093 **21**. Syphilis CDNA National Guidelines for Public Health Units v1.1, June 2018 **22**. Acquah R et al. Sex Transm Infect 2017;93:326 **23**. Scott LJ Sex Transm Infect 2018 65:37-539 **24**. https://www.dhhs.nh.gov/media/pr/2017/06222017syphilis.htm **25**. Bright A & Dups J, Communicable Diseases Intelligence Volume 40 No 1 - March 2016 **26**. Arizona Dept. Health & Services, Real-Time Syphilis Data 2018 **27**. Mokany E et al. Clin. Chem. 2013; 59(2): 419-426 **28**. PlexPCR[®] VHS Instructions for use *Not for sale in USA. *PlexPCR[®]* VHS kits are developed and manufactured by **SpeeDx** Pty Ltd, Sydney. *PlexPCR[®] & SpeeDx[®]* are registered trademarks of **SpeeDx** Pty Ltd. Other copyright and trademarks are the property of the respective owners. **SpeeDx** Pty Ltd products may be covered by one or more local or f

Australia - SpeeDx Pty. Ltd.

+61 (0)2 9209 4170 sales@speedx.com.au

Suite G16, National Innovation Centre 4 Cornwallis Street, Sydney NSW 2015 Australia

Europe - SpeeDx Ltd.

+44 (0)333 577 5210

sales.uk@speedx.com.au

Acre House 11/15 William Road London NW1 3ER United Kingdom



Find out more plexpcr.com